Table 5.
Neoadjuvant treatment adverse effects.
| Baseline Variable | C-SAP group (n=33) | SAP group (n=95) | P* value | SOX group (n=72) | P# value | P& value |
|---|---|---|---|---|---|---|
| WBC decreased | 0.461 | 0.103 | 0.005 | |||
| Grade 0, 1, 2 | 28 (84.8) | 75 (78.9) | 68 (94.4) | |||
| Grade 3, 4 | 5 (15.2) | 20 (21.1) | 4 (5.6) | |||
| Neutrophil count decreased | 0.899 | 0.048 | 0.023 | |||
| Grade 0, 1, 2 | 25 (75.8) | 73 (76.8) | 65 (90.3) | |||
| Grade 3, 4 | 8 (24.8) | 22 (23.2) | 7 (9.7) | |||
| Anemia | 1.000 | 0.422 | 0.122 | |||
| Grade 0, 1, 2 | 32 (97.0) | 93 (97.9) | 67 (93.1) | |||
| Grade 3, 4 | 1 (3.0) | 2 (2.1) | 5 (6.9) | |||
| Platelet count decreased | 0.458 | 0.918 | 0.444 | |||
| Grade 0, 1, 2 | 31 (93.9) | 92 (96.8) | 68 (94.4) | |||
| Grade 3, 4 | 2 (6.1) | 3 (3.2) | 4 (5.6) | |||
| Serum AST/ALT increase | 0.114 | 0.695 | 0.154 | |||
| Normal | 25 (75.8) | 83 (87.4) | 57 (79.2) | |||
| Increase | 8 (24.2) | 12 (12.6) | 15 (20.8) | |||
| Febrile neutropenia | 0.601 | 1.000 | 0.427 | |||
| No | 32 (97.0) | 90 (94.7) | 70 (97.2) | |||
| Yes | 1 (3.0) | 5 (5.3) | 2 (2.8) |
P*, C-SAP vs SAP; P#, C-SAP vs SOX; P&, SAP vs SOX.